SEC Form 4 · accession 0001209191-16-149491
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Azelby
Officer — EVP & Chief Commercial Officer
Period of report
Nov 8, 2016
Accepted (ET)
Nov 10, 2016 · 8:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 8, 2016 | A | 10,000 | $0.00 | A | 48,640 | D | |
| Common StockF2 | Nov 10, 2016 | S | 12,921 | $24.135 | D | 35,719 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $25.29 | Nov 8, 2016 | A | 40,000 | A | — | Nov 7, 2026 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of November 8, 2016.
- F2The sale reported on this Form 4 was effected pursuant to an Issuer approved Rule 10b5-1 compliant sell-to-cover award, in order to cover tax withholding incident to the vesting of 38,640 RSUs. The number of shares sold to cover such withholding obligations was determined based on the trade price, which is equal to the average of the high and low prices of the Issuer's common stock on November 2, 2016, the next trading day following the date on which the RSUs vested.
- F31/48th of the shares subject to the option become vested and exercisable on December 8, 2016 and 1/48th of the shares subject to the option shall vest monthly thereafter.